Fukui-Kawaura Sachi, Kawahara Takashi, Araki Yushi, Nishimura Reona, Uemura Koichi, Namura Kazuhiro, Mizuno Nobuhiko, Yao Masahiro, Uemura Hiroji, Ikeda Ichiro
Department of Urology, Yokohama Minami Kyousai Hospital, Yokohama, Japan.
Department of Urology, Yokohama City University, Graduate School of Medicine, Yokohama, Japan.
Oncotarget. 2021 Apr 27;12(9):917-922. doi: 10.18632/oncotarget.27944.
High-risk non-muscle invasive bladder cancer (NMIBC) is thought to be associated with a higher risk of recurrence and progression. A recent study revealed that a high De Ritis ratio was a risk factor in some solid malignancies. This study examined the importance of the De Ritis ratio as a prognostic marker in high-risk NMIBC.
A total of 138 patients who were initially diagnosed with high-risk NMIBC between January 2012 to December 2016 were enrolled in this study. The criteria for the high-risk classification followed the EAU guidelines. The recurrence-free and progression-free survival of the higher and lower De Ritis ratio groups were compared. The cut-off value of the De Ritis ratio was set at 1.35, based on a receiver operator curve analysis.
The median observation period was 50.3 months. Among these patients, 32 (23.1%) patients developed recurrent disease and 15 (10.9%) patients showed progression. A multivariate analysis revealed that non-BCG treatment was an independent risk factor for recurrence, and a higher De Ritis ratio was an independent risk factor for cancer progression.
The De Ritis ratio might be a risk factor for progression in high-risk NMIBC.
高危非肌层浸润性膀胱癌（NMIBC）被认为与较高的复发和进展风险相关。最近一项研究表明，高De Ritis比值是一些实体恶性肿瘤的危险因素。本研究探讨了De Ritis比值作为高危NMIBC预后标志物的重要性。
本研究共纳入了2012年1月至2016年12月期间最初诊断为高危NMIBC的138例患者。高危分类标准遵循欧洲泌尿外科学会（EAU）指南。比较了高De Ritis比值组和低De Ritis比值组的无复发生存率和无进展生存率。基于受试者工作特征曲线分析，将De Ritis比值的临界值设定为1.35。
中位观察期为50.3个月。在这些患者中，32例（23.1%）出现复发，15例（10.9%）出现进展。多因素分析显示，非卡介苗治疗是复发的独立危险因素，而较高的De Ritis比值是癌症进展的独立危险因素。
De Ritis比值可能是高危NMIBC进展的危险因素。
